Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) EBITDA Margin (2016 - 2025)

Adma Biologics (ADMA) has disclosed EBITDA Margin for 13 consecutive years, with 45.09% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 1249.0% year-over-year to 45.09%, compared with a TTM value of 37.53% through Dec 2025, up 493.0%, and an annual FY2025 reading of 37.53%, up 493.0% over the prior year.
  • EBITDA Margin was 45.09% for Q4 2025 at Adma Biologics, up from 38.01% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 45.09% in Q4 2025 and bottomed at 94.49% in Q1 2021.
  • Average EBITDA Margin over 5 years is 6.36%, with a median of 3.55% recorded in 2023.
  • The sharpest move saw EBITDA Margin soared 13250bps in 2021, then crashed -4419bps in 2022.
  • Year by year, EBITDA Margin stood at 23.98% in 2021, then tumbled by -184bps to 68.17% in 2022, then surged by 128bps to 19.26% in 2023, then surged by 69bps to 32.6% in 2024, then skyrocketed by 38bps to 45.09% in 2025.
  • Business Quant data shows EBITDA Margin for ADMA at 45.09% in Q4 2025, 38.01% in Q3 2025, and 35.08% in Q2 2025.